Preferred Label : Glucagon-Like Peptide-1 Receptor;

MeSH definition : A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS).;

MeSH synonym : Glucagon Like Peptide 1 Receptor; Peptide-1 Receptor, Glucagon-Like; Receptor, Glucagon-Like Peptide-1; GLP-1R Receptor; GLP 1R Receptor; Receptor, GLP-1R; GLP1R Protein; Protein, GLP1R; GLP-1 Receptor; GLP 1 Receptor; Receptor, GLP-1; GLP1R Receptor; Receptor, GLP1R;

Details


Main resources

You can consult :

A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS).

https://www.acadpharm.org/publications/page.php?rb1=50&id_doc=7184
2024
France
scientific and technical information
parkinson's disease, nos
Intensity and Distress 1
One
Fear Score 1
Histone-Lysine N-Methyltransferase EHMT1
CDISC SDTM Model Version 1.5
Agreement Score 1
Thought Score 1
Symptoms Extent Score 1
Guadeloupe
Phase I Trial
Upset Score 1
Glucagon-Like Peptide-1 Receptor
Severity of Symptom Score 1
Mild Adverse Event
One Hundred Percent
One Full Term Pregnancy
Illness Intrusiveness Rating 1
Parkinson's Disease Pathway KEGG
glucagon-like peptide 1
Never Smoker
Parkinson Disease
Gleason Grade Group 1
ECOG Performance Status 1
Receptor
Neck Pain Score 1
What Month is it
1+ Score, WHO
1+ Score
CDISC SDTM Model Version 1.6
Tumor Regression Score 1
Clinical Status Ordinal Scale Outcome 1
parkinson disease

---
https://ansm.sante.fr/actualites/diabete-de-type-2-et-tensions-dapprovisionnement-conduite-a-tenir-pour-la-prescription-des-analogues-de-glp1
2023
false
false
false
France
French
incretins
Glucagon-Like Peptide-1 Receptor
guideline
semaglutide
semaglutide
continuity of patient care
hypoglycemic agents
diabetes mellitus, type 2
guidelines for drug use
Liraglutide
break in supply
liraglutide

---
https://www.cochrane.org/fr/CD013650/VASC_les-effets-des-inhibiteurs-de-la-dpp-4-des-agonistes-des-recepteurs-du-glp-1-et-des-inhibiteurs-du
2021
United Kingdom
review of literature
french abstract
glucagon-like peptide 1
Glucagon-Like Peptide-1 Receptor
cardiovascular diseases
disease
Glucagon-Like Peptide-2 Receptor
persons
glucagon-like peptide 2
Diseases of the cardiovascular system
dipeptidyl-peptidase iv inhibitors
Sodium-Glucose Transporter 2 Inhibitors
Diseases
Disease
premature separation of placenta
disease of cardiovascular system, nos

---
https://rmlg.uliege.be/article/2974
2018
false
false
false
false
Belgium
French
journal article
diabetes mellitus, type 2
cardiovascular diseases
hypoglycemic agents
empagliflozin
treatment outcome
empagliflozin
Sodium-Glucose transporter 2
comparative effectiveness research
Liraglutide
liraglutide
Glucagon-Like Peptide-1 Receptor
incretins
case reports
prognosis
cardiovascular diseases
drug therapy, combination
diabetes mellitus, type 2
renal insufficiency, chronic
belgium
insurance, health, reimbursement
Clinical Decision-Making
risk factors
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
glucosides

---
https://www.ema.europa.eu/medicines/human/EPAR/Ozempic
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
semaglutide
semaglutide
drug approval
europe
treatment outcome
adult
diabetes mellitus, type 2
injections, subcutaneous
Pre-filled Pen Syringe
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin
cardiovascular diseases
diabetes complications
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
semaglutide
glucagon-like peptides
glucagon-like peptides

---
https://www.revmed.ch/RMS/2017/RMS-N-571/Options-therapeutiques-chez-un-patient-diabetique-de-type-2-mal-controle-par-une-insuline-basale
2017
false
false
false
Switzerland
French
journal article
diabetes mellitus, type 2
administration, oral
insulin
injections, subcutaneous
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
SGLT2 Inhibitor
Sodium-Glucose transporter 2
drug therapy, combination
Glucagon-Like Peptide-1 Receptor
drug combinations
Sodium-Glucose Transporter 2 Inhibitors

---
http://www.revmed.ch/RMS/2014/RMS-N-439/Interet-d-une-combinaison-agoniste-des-recepteurs-du-GLP-1-et-insuline-basale-dans-le-traitement-du-diabete-de-type-2
2014
false
false
false
Switzerland
French
journal article
drug therapy, combination
hypoglycemic agents
diabetes mellitus, type 2
insulin
treatment outcome
Substance with glucagon-like peptide 1 receptor agonist mechanism of action (substance)
incretins
drug combinations
blood glucose
gastric emptying
injections, subcutaneous
Delayed-Action preparations
hyperglycemia, postprandial
semaglutide
rGLP-1 protein
body weight
Liraglutide
Glucagon-Like Peptide-1 Receptor
lixisenatide
hyperglycemia
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
peptides
venoms
glucagon-like peptide 1
glucagon-like peptide 1
Exenatide

---
http://www.amub-ulb.be/revue-medicale-bruxelles/article/les-nouveaux-anti-diabetiques-oraux-1032
2014
false
false
false
false
Belgium
French
journal article
comparative study
diabetes mellitus, type 2
incretins
hypoglycemic agents
administration, oral
incretins
gastric inhibitory polypeptide
glucagon-like peptide 1
dipeptidyl-peptidase iv inhibitors
dipeptidyl peptidase 4 (DPP-4) inhibitors
other blood glucose lowering drugs, excl. insulins
incretins
hypoglycemic agents
hypoglycemic agents
SLC5A2 protein, human
risk factors
drug therapy, combination
treatment outcome
Glucagon-Like Peptide-1 Receptor
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose transporter 2

---
https://www.revmed.ch/RMS/2009/RMS-206/Role-et-place-des-analogues-du-GLP-1-dans-le-traitement-du-diabete-de-type-2
2009
false
Switzerland
French
Liraglutide
Glucagon-Like Peptide-1 Receptor
exenatide
liraglutide
diabetes mellitus, type 2
glucagon-like peptide 1
Product containing glucagon-like peptide 1 receptor agonist (product)
Substance with glucagon-like peptide 1 receptor agonist mechanism of action (substance)
hypoglycemic agents
peptides
venoms
journal article
Exenatide
incretins

---
Nous contacter.
18/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.